A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy.
Robert Dreicer
Consultant or Advisory Role - EMD Serono; Janssen; Lilly; Millennium; Sanofi
Honoraria - Janssen; Millennium
Research Funding - Millennium
David B. Agus
Consultant or Advisory Role - Millennium
Joaquim Bellmunt
Consultant or Advisory Role - Takeda
Johann Sebastian De Bono
Consultant or Advisory Role - Astellas Pharma; Johnson & Johnson; Medivation; Sanofi
Honoraria - Astellas Pharma; Johnson & Johnson; Medivation; Sanofi
Research Funding - AstraZeneca
Daniel Peter Petrylak
Consultant or Advisory Role - Centicor; Millennium
Bindu Tejura
Employment or Leadership Position - Millennium
Yuanjun Shi
Employment or Leadership Position - Millennium
Karim Fizazi
Consultant or Advisory Role - Millennium
Research Funding - Millennium